MiR-34b is associated with clinical outcome in triple-negative breast cancer patients

por Svoboda, Marek, Sana, Jiri, Redova, Martina, Navratil, Jiri, Palacova, Marketa, Fabian, Pavel, Slaby, Ondrej, Vyzula, Rostislav
Publicado 2012

Genetic and Preventive Services for Hereditary Breast and Ovarian Cancer in the Czech Republic

por Foretova, Lenka, Petrakova, Katarina, Palacova, Marketa, Kalabova, Renata, Navratilova, Marie, Lukesova, Miroslava, Vasickova, Petra, Machackova, Eva, Kleibl, Zdenek, Pohlreich, Petr
Publicado 2006

Ribociclib Plus Letrozole in Patients with Hormone Receptor-positive, HER2-negative Advanced Breast Cancer with No Prior Endocrine Therapy: Subgroup Safety Analysis from The Phase...

por Borstnar, Simona, Palacova, Marketa, Łacko, Aleksandra, Timcheva, Constanta, Gal-Yam, Einav Nili, Papazisis, Konstantinos, Beniak, Juraj, Kudela, Pavol, Rubovszky, Gábor
Publicado 2022

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

por Saura, Cristina, Oliveira, Mafalda, Feng, Yin-Hsun, Dai, Ming-Shen, Chen, Shang-Wen, Hurvitz, Sara A., Kim, Sung-Bae, Moy, Beverly, Delaloge, Suzette, Gradishar, William, Masuda, Norikazu, Palacova, Marketa, Trudeau, Maureen E., Mattson, Johanna, Yap, Yoon Sim, Hou, Ming-Feng, De Laurentiis, Michelino, Yeh, Yu-Min, Chang, Hong-Tai, Yau, Thomas, Wildiers, Hans, Haley, Barbara, Fagnani, Daniele, Lu, Yen-Shen, Crown, John, Lin, Johnson, Takahashi, Masato, Takano, Toshimi, Yamaguchi, Miki, Fujii, Takaaki, Yao, Bin, Bebchuk, Judith, Keyvanjah, Kiana, Bryce, Richard, Brufsky, Adam
Publicado 2020